DD132968B3 - Neue spirolactone und verfahren zur deren herstellung - Google Patents
Neue spirolactone und verfahren zur deren herstellung Download PDFInfo
- Publication number
- DD132968B3 DD132968B3 DD77202077A DD20207777A DD132968B3 DD 132968 B3 DD132968 B3 DD 132968B3 DD 77202077 A DD77202077 A DD 77202077A DD 20207777 A DD20207777 A DD 20207777A DD 132968 B3 DD132968 B3 DD 132968B3
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- methylene
- perhydrofuran
- spiro
- oxo
- water
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- 229960002256 spironolactone Drugs 0.000 title description 5
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 title description 5
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229940083712 aldosterone antagonist Drugs 0.000 description 2
- 239000002170 aldosterone antagonist Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 2
- 229960003654 desoxycortone Drugs 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 2
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 description 1
- -1 alkyl radicals Chemical class 0.000 description 1
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000004281 calcium formate Substances 0.000 description 1
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- KOODSCBKXPPKHE-UHFFFAOYSA-N propanethioic s-acid Chemical compound CCC(S)=O KOODSCBKXPPKHE-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/007—3 membered carbocyclic rings in position 6-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/001—Lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2652761A DE2652761C2 (de) | 1976-11-16 | 1976-11-16 | 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DD132968A5 DD132968A5 (de) | 1978-11-22 |
| DD132968B3 true DD132968B3 (de) | 1991-03-28 |
Family
ID=5993550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD77202077A DD132968B3 (de) | 1976-11-16 | 1977-11-14 | Neue spirolactone und verfahren zur deren herstellung |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4129564A (forum.php) |
| JP (2) | JPS5363373A (forum.php) |
| AT (1) | AT356827B (forum.php) |
| AU (1) | AU512611B2 (forum.php) |
| BE (1) | BE860877A (forum.php) |
| CA (1) | CA1092094A (forum.php) |
| CH (2) | CH631463A5 (forum.php) |
| CS (1) | CS194823B2 (forum.php) |
| DD (1) | DD132968B3 (forum.php) |
| DE (1) | DE2652761C2 (forum.php) |
| DK (1) | DK141967C (forum.php) |
| ES (1) | ES464193A1 (forum.php) |
| FR (1) | FR2370755A1 (forum.php) |
| GB (1) | GB1550568A (forum.php) |
| GR (1) | GR65227B (forum.php) |
| HU (1) | HU174983B (forum.php) |
| IE (1) | IE46076B1 (forum.php) |
| IL (1) | IL53353A (forum.php) |
| IT (1) | IT1092262B (forum.php) |
| LU (1) | LU78514A1 (forum.php) |
| NL (1) | NL7711946A (forum.php) |
| SE (1) | SE436425B (forum.php) |
| SU (2) | SU695560A3 (forum.php) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2922500A1 (de) * | 1979-05-31 | 1980-12-04 | Schering Ag | 6 beta .7 beta |
| DE3022337A1 (de) * | 1980-06-11 | 1982-01-07 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen |
| DE3051166C2 (en) * | 1980-06-11 | 1990-10-18 | Schering Ag, 1000 Berlin Und 4709 Bergkamen, De | Compsns. for contraception or treatment of gynaecological disorders |
| DE3111951A1 (de) * | 1981-03-23 | 1982-09-30 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| DE3265852D1 (en) * | 1981-09-21 | 1985-10-03 | Schering Ag | 3-beta,7-beta,15-alpha-trihydroxy-5-androsten-17-one, its 3,15-dipivalate, and its preparation |
| DE3213962A1 (de) * | 1982-04-13 | 1983-10-13 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1(alpha).2(alpha);6(beta).7(beta).15(beta).16(beta)-trimethylen-3-oxo-17(alpha)-pregn-4-en-21.17-carbolacton, dessen herstellung und verwendung als arzneimittel |
| DE3227598A1 (de) * | 1982-07-22 | 1984-01-26 | Schering AG, 1000 Berlin und 4709 Bergkamen | 7(alpha)-acylthio-15.16-methylen-3-oxo-17(alpha)-pregna-1.4-dien-21,17-carbolactone, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| DE3234972A1 (de) * | 1982-09-17 | 1984-03-22 | Schering AG, 1000 Berlin und 4709 Bergkamen | 7(alpha)-alkyl-17(alpha)-pregn-4-en-21.17-carbolactone und -21-carbonsaeuresalze sowie verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| DE3240510A1 (de) * | 1982-10-29 | 1984-05-03 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue 7(alpha)-acylthio-1(alpha),2(alpha)-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, deren herstellung und diese enthaltende arzneimittel |
| JPS59139400A (ja) * | 1983-01-31 | 1984-08-10 | Shionogi & Co Ltd | 抗アルドステロン活性ステロイド誘導体 |
| DE3306554A1 (de) * | 1983-02-22 | 1984-08-23 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur herstellung von 3-((delta)(pfeil hoch)4(pfeil hoch)-3-ketosteroid-17(alpha)-yl)-propionsaeurelactonen |
| US4559332A (en) * | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
| ATE51233T1 (de) * | 1983-08-17 | 1990-04-15 | Schering Ag | 7-alpha-substituierte 3-oxo-17alpha-pregn-4-en21.17-carbolactone, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate. |
| DE3347510A1 (de) * | 1983-12-27 | 1985-08-01 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur herstellung von 3-oxo-17(alpha)-pregna-4,6-dien-21,17-carbolactonen |
| DE3402329A1 (de) * | 1984-01-20 | 1985-08-01 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| US4670551A (en) * | 1984-06-21 | 1987-06-02 | Ciba-Geigy Corporation | Epoxy steroids |
| JPS6248694A (ja) * | 1985-08-28 | 1987-03-03 | Shionogi & Co Ltd | 抗アルドステロン活性ステロイド誘導体 |
| DE3544661A1 (de) * | 1985-12-13 | 1987-06-19 | Schering Ag | Verfahren zur herstellung von 7(alpha)-acetylthiosteroiden |
| JPS62132932U (forum.php) * | 1986-02-14 | 1987-08-21 | ||
| US4837211A (en) * | 1987-04-06 | 1989-06-06 | Carolina Medical Products, Inc. | Spironolactone composition |
| JPS6453026U (forum.php) * | 1987-09-29 | 1989-03-31 | ||
| DE3916112A1 (de) * | 1989-05-16 | 1990-11-22 | Schering Ag | Dihydrospirorenon als antiandrogen |
| DE4344462C2 (de) | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| DE69620756T2 (de) * | 1995-06-07 | 2002-11-14 | G.D. Searle & Co., Chicago | Kombinationstherapie zur behandlung des kongestiven herzversagens mit spironolacton und angiotensin ii-antagonist |
| DE19633685C1 (de) * | 1996-08-12 | 1997-10-09 | Schering Ag | Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens |
| DE19651000A1 (de) * | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
| PL348198A1 (en) * | 1998-11-06 | 2002-05-06 | Searle & Co | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| PT1380301E (pt) | 1999-08-31 | 2009-03-30 | Bayer Schering Pharma Ag | Combinação farmacêutica compreendendo etinilestradiol e drospirenona para utilização como contraceptivo |
| EP2305267A3 (en) | 1999-08-31 | 2011-08-17 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
| US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| RU2269342C9 (ru) * | 1999-08-31 | 2007-10-27 | Шеринг Акциенгезелльшафт | Фармацевтическая комбинация этинилэстрадиола и дроспиренона для использования в качестве контрацептива |
| ATE442147T1 (de) * | 2000-01-18 | 2009-09-15 | Bayer Schering Pharma Ag | Pharmazeutische zubereitung enthaltend drospirenon |
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| US6716829B2 (en) | 2000-07-27 | 2004-04-06 | Pharmacia Corporation | Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders |
| EP1368009A2 (en) * | 2000-07-27 | 2003-12-10 | Pharmacia Corporation | Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| EP1216712A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Cyclodextrin-drospirenone inclusion complexes |
| EP1216713A1 (en) * | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| EP1406634A1 (en) * | 2001-07-13 | 2004-04-14 | Schering Aktiengesellschaft | Combination of drospirenone and an estrogen sulphamate for hrt |
| BR0308515A (pt) * | 2002-03-18 | 2005-02-01 | Pharmacia Corp | Combinação de um antagonista de receptor de aldosterona com ácido nicotìnico ou um derivado de ácido nicotìnico |
| CA2479259A1 (en) * | 2002-03-18 | 2003-10-02 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and a bile acid sequestering agent |
| ITMI20040367A1 (it) * | 2004-03-01 | 2004-06-01 | Ind Chimica Srl | Processo per la preparazione di drospirenone |
| US20050220825A1 (en) * | 2004-03-10 | 2005-10-06 | Adrian Funke | Molecular dispersions of drospirenone |
| HUP0402466A2 (en) * | 2004-11-30 | 2006-07-28 | Richter Gedeon Vegyeszet | Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main, intermediates of the process |
| HUP0402465A2 (en) * | 2004-11-30 | 2006-07-28 | Richter Gedeon Vegyeszet | Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main intermediates of the process |
| US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
| US20090023914A1 (en) * | 2007-05-01 | 2009-01-22 | Alessandro Pontiroli | Process for preparing drospirenone and intermediate thereof |
| FR2917975B1 (fr) | 2007-06-26 | 2009-10-16 | Ceva Sante Animale Sa | Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains |
| US20090035373A1 (en) * | 2007-07-31 | 2009-02-05 | Katrin Mittmann | Pharmaceutical composition for contraception and blood pressure regulation, kit for contraception containing same and method of production of same |
| US20090035374A1 (en) * | 2007-07-31 | 2009-02-05 | Katrin Mittmann | Method of making a single-stage pharmaceutical preparation for oral therapy to regulate blood pressure and kit containing same |
| HUP0700826A3 (en) | 2007-12-20 | 2010-03-29 | Richter Gedeon Nyrt | Coated tablet containing drospirenone and process for producing the same |
| US7960368B2 (en) * | 2008-03-05 | 2011-06-14 | Everstra, Inc. | Bismethylene-17A carbolactones and related uses |
| WO2010068500A2 (en) * | 2008-11-25 | 2010-06-17 | Evestra, Inc. | PROGESTATIONAL 3-(6,6-ETHYLENE-17b-HYDROXY-3-OXO-17a-PREGNA-4-ENE-17a -YL) PROPIONIC ACID g-LACTONES |
| US20120114757A1 (en) | 2009-02-18 | 2012-05-10 | Bayer Pharma Aktiengesellschaft | Particles comprising drospirenone encapsulated in a polymer |
| CA2752805A1 (en) | 2009-02-18 | 2010-08-26 | Bayer Pharma Aktiengesellschaft | Formulation comprising drospirenone for subcutaneous or intramuscular administration |
| US8334375B2 (en) * | 2009-04-10 | 2012-12-18 | Evestra, Inc. | Methods for the preparation of drospirenone |
| ES2432063T3 (es) * | 2009-06-16 | 2013-11-29 | Crystal Pharma, S.A.U. | Procedimiento para la obtención de 17-espirolactonas en esteroides |
| JP6148175B2 (ja) | 2010-05-10 | 2017-06-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 網膜中および／または網膜下における液体貯留の処置のための方法および組成物 |
| JP6180930B2 (ja) | 2010-06-16 | 2017-08-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 創傷治癒過程における再上皮化を刺激するための方法及び組成物 |
| AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
| US11351122B1 (en) | 2010-07-28 | 2022-06-07 | Laboratorios Leon Farma Sa | Synthetic progestogens and pharmaceutical compositions comprising the same |
| US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| CN102887934B (zh) * | 2012-09-20 | 2015-05-27 | 杭州福斯特药业有限公司 | 一种屈螺酮的制备方法 |
| WO2016063269A1 (en) | 2014-10-20 | 2016-04-28 | Prendergast Patrick T | Use of antagonists to the nuclear steroid receptor alone or in combination as direct antiviral agents to inhibit alphavirus, togaviridae, arenaviridae, filoviridae, bunyaviridae, flaviviridae and rhabdoviridae |
| HUE065350T2 (hu) | 2015-06-23 | 2024-05-28 | Laboratorios Leon Farma Sa | Drospirenonalapú fogamzásgátló túlsúllyal érintett nõi beteg számára |
| EP3108889A1 (en) | 2015-06-23 | 2016-12-28 | Philippe Perrin | Drospirenone-based contraceptive for a female patient affected with excess weight |
| WO2017055248A1 (en) | 2015-09-28 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of heart failure |
| US20180280414A1 (en) | 2015-10-13 | 2018-10-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| EP3490606B8 (en) | 2016-07-26 | 2024-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| EP4134082A1 (en) | 2021-08-12 | 2023-02-15 | Chemo Research, S.L. | Method for treating endometriosis and providing effective contraception |
| US20240366632A1 (en) | 2021-08-31 | 2024-11-07 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of ocular rosacea |
| WO2023152658A1 (en) | 2022-02-10 | 2023-08-17 | Lupin Limited | Slow release drospirenone tablet composition |
| WO2023165988A1 (en) | 2022-03-01 | 2023-09-07 | Chemo Research, S.L. | Chewable oral contraceptive |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3257390A (en) * | 1963-06-12 | 1966-06-21 | Merck & Co Inc | Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents |
| NL166267C (nl) * | 1968-03-22 | 1981-07-15 | Merck & Co Inc | Werkwijze ter bereiding van farmaceutische preparaten, de onder toepassing daarvan verkregen gevormde voort- brengselen, alsmede werkwijze ter bereiding van 6,7-methyleen-20-spirox-4-en-3-onderivaten met aldoste- ron remmende werking. |
| DE2237143A1 (de) * | 1972-07-28 | 1974-02-14 | Hoechst Ag | Verfahren zur herstellung von beta(3-keto-7alpha-acetylthio-17beta-hydroxy4-androsten-17alpha-yl)-propionsaeuregamma-lacton und dessen 1-dehydro-derivat |
| CH601352A5 (forum.php) * | 1973-09-26 | 1978-07-14 | Hoffmann La Roche |
-
1976
- 1976-11-16 DE DE2652761A patent/DE2652761C2/de not_active Expired
-
1977
- 1977-10-31 NL NL7711946A patent/NL7711946A/xx not_active Application Discontinuation
- 1977-11-03 SU SU772537651A patent/SU695560A3/ru active
- 1977-11-04 IE IE2247/77A patent/IE46076B1/en not_active IP Right Cessation
- 1977-11-08 CH CH1361677A patent/CH631463A5/de not_active IP Right Cessation
- 1977-11-09 AU AU30509/77A patent/AU512611B2/en not_active Expired
- 1977-11-10 IL IL53353A patent/IL53353A/xx unknown
- 1977-11-11 US US05/850,524 patent/US4129564A/en not_active Expired - Lifetime
- 1977-11-14 GR GR54787A patent/GR65227B/el unknown
- 1977-11-14 LU LU78514A patent/LU78514A1/xx unknown
- 1977-11-14 DD DD77202077A patent/DD132968B3/de unknown
- 1977-11-15 IT IT29658/77A patent/IT1092262B/it active
- 1977-11-15 AT AT815577A patent/AT356827B/de not_active IP Right Cessation
- 1977-11-15 GB GB47440/77A patent/GB1550568A/en not_active Expired
- 1977-11-15 HU HU77SCHE630A patent/HU174983B/hu unknown
- 1977-11-15 SE SE7712891A patent/SE436425B/xx not_active IP Right Cessation
- 1977-11-16 CA CA291,065A patent/CA1092094A/en not_active Expired
- 1977-11-16 DK DK508077A patent/DK141967C/da not_active IP Right Cessation
- 1977-11-16 CS CS777551A patent/CS194823B2/cs unknown
- 1977-11-16 BE BE182661A patent/BE860877A/xx not_active IP Right Cessation
- 1977-11-16 ES ES464193A patent/ES464193A1/es not_active Expired
- 1977-11-16 FR FR7734434A patent/FR2370755A1/fr active Granted
- 1977-11-16 JP JP13775877A patent/JPS5363373A/ja active Granted
-
1979
- 1979-01-11 SU SU792706061A patent/SU743582A3/ru active
-
1982
- 1982-02-09 CH CH79382A patent/CH632774A5/de not_active IP Right Cessation
-
1985
- 1985-09-27 JP JP60212779A patent/JPS61218595A/ja active Granted
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD132968B3 (de) | Neue spirolactone und verfahren zur deren herstellung | |
| EP0019690B1 (de) | 6 beta.7 beta; 15.16-Dimethylen-1.4-androstadien-3-one, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel | |
| EP0100874A2 (de) | Neue 6,16-Dimethylkortikoide, ihre Herstellung und Verwendung | |
| EP0061418B1 (de) | 7-Alpha-Alkoxycarbonyl-15-beta.16-beta-methylen-4-androstene, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel | |
| DE2404946A1 (de) | Neue steroidverbindungen, verfahren zu ihrer herstellung und deren verwendung | |
| AT366391B (de) | Verfahren zur herstellung von neuen spirolactonen | |
| DE2248834A1 (de) | Verfahren zur herstellung von beta(3-keto-7 alpha-acetylthio-17beta-hydroxy4-androsten-17 alpha-yl)-propionsaeuregamma -lacton | |
| DE2531145C2 (de) | Verfahren zur Herstellung von 11beta-Hydroxy-18-alkyl-steroiden der Östranreihe | |
| DE1226573B (de) | Verfahren zur Herstellung von 1, 2beta-Methylensteroiden | |
| DE2609695A1 (de) | 7-substituierte 4-androsten-3-one und verfahren zu ihrer herstellung | |
| AT253135B (de) | Verfahren zur Herstellung neuer Steroidverbindungen | |
| DE1907804C3 (de) | 4-Chlor-1alpha,2alpha;6alpha,7alphadimethylen-3-keto-4-pregnene, Verfahren zu deren Herstellung sowie diese enthaltendes Mittel | |
| US3002981A (en) | Androstene-16-ones | |
| DE2646043C2 (de) | 7α-Acetylthio-6α-methyl-4-androsten-3-one, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| AT253704B (de) | Verfahren zur Herstellung des neuen 7α-Methyl-16α-hydroxy-östrons und seines 3, 16-Diacetates | |
| DE1468638A1 (de) | Neue Cyclopentanophenanthren-Derivate und Verfahren zu deren Herstellung | |
| DE2336438A1 (de) | Verfahren zur herstellung von 17 betaoxalylsteroiden | |
| DE1668205B2 (de) | 16 alpha-alkylthio-9beta, 10alphasteroide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate | |
| DE1593448C (de) | 13beta-Äthyl-gon-4-en-3-on-thioketale, deren Herstellung und diese enthaltendes Mittel | |
| DE1443546C (de) | Verfahren zur Herstellung von 6 Methyl Delta hoch 14 steroiden der Pregnanreihe | |
| DE3140823A1 (de) | 6-chlor-6.7;15ss.16ss-dimethylen-3-keto-steroid- 21.17-carbolactone, verfahren zu ihrer herstellung und verwendung als arzneimittel | |
| DE2627186A1 (de) | 7-substituierte 4-androsten-3-one und verfahren zu ihrer herstellung iii | |
| DE1643012B2 (de) | Verfahren zur herstellung von butenoliden | |
| DE1094258B (de) | Verfahren zur Herstellung von fluorierten 16-Methylsteroiden | |
| DE2722706A1 (de) | 15.16-methylen-androsta-4.15-dien- 3-one und verfahren zu ihrer herstellung |